Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
ADMA Biologics, Inc. (NASDAQ:ADMA), a company that has delivered an impressive 101% return to investors over the past year according to InvestingPro data, conducted its 2025 Annual Meeting of Stockholders on Wednesday. The meeting took place virtually, with four key proposals submitted for a vote.
The company successfully elected two Class III directors, Jerrold B. Grossman, D.P.S., and Lawrence P. Guiheen, to serve until the 2028 Annual Meeting. Grossman received 165,120,823 votes in favor, while Guiheen secured 133,835,725 votes. Both directors will hold their positions until their successors are elected or until their earlier resignation, removal, or death.
Additionally, stockholders ratified the appointment of KPMG LLP as ADMA Biologics’ independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 204,623,833 votes in favor, with 269,649 against and 127,057 abstentions.
The meeting also addressed executive compensation, where the Say-on-Pay proposal was approved with 161,456,980 votes in favor. This non-binding advisory vote allows stockholders to express their approval or disapproval of the compensation of the company’s named executive officers.
Lastly, the frequency of future advisory votes on executive compensation, known as the Say-on-Frequency proposal, was determined. The majority voted for an annual advisory vote, with 173,069,853 votes supporting this frequency.
ADMA Biologics reported a quorum for the meeting, with 205,020,539 shares represented virtually or by proxy out of the 238,563,612 shares outstanding as of the April 8, 2025 record date.
The information is based on a press release statement from ADMA Biologics filed with the Securities and Exchange Commission.
In other recent news, ADMA Biologics reported a strong performance for Q1 2025, with revenue reaching $114.8 million, surpassing forecasts and marking a 40% increase year-over-year. The company also achieved a gross profit of $61.1 million and an adjusted EBITDA of $47.9 million, reflecting an 81% growth compared to the previous year. Despite voluntary product withdrawals impacting revenue by $3.8 million, ADMA Biologics maintained a positive outlook with FDA approval for a new yield enhancement production process, which is expected to boost output efficiency. The company projects its 2025 revenue to reach at least $500 million, with an adjusted EBITDA of $235 million or more. Analysts from firms like Mizuho (NYSE:MFG) and Cantor Fitzgerald have taken note of these developments, with ADMA’s recent FDA clearance being a significant highlight. Additionally, ADMA Biologics announced a $500 million stock repurchase program, aiming to strengthen shareholder confidence. The company continues to focus on expanding its plasma collection centers and is optimistic about its future growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.